Replies to post #218390 on Biotech Values

[ronpopeil]

Citron Research, the notable short-selling research firm, blasted AveXis in a report dated December 14. The firm believes the stock is the "next biotech blowup," and the stock could plummet to $9 per share over the next 12 months and $5 over the next 24 months"

[DewDiligence]

NVS acquires AVXS for $218/sh in cash—an 88% premium to Friday’s close:

https://finance.yahoo.com/news/avexis-enters-agreement-acquired-novartis-044500719.html

The nominal deal value is $8.7B.